Climb Bio, Inc.

Climb Bio Inc is a clinical-stage biotechnology company focused on developing therapies for immune-mediated diseases. Its lead product candidate is budoprutug, an anti-CD19 monoclonal antibody designed to treat B-cell mediated diseases. Budoprutug is currently in Phase 2 clinical trials for primary membranous nephropathy and immune thrombocytopenia, and in a Phase 1b trial for systemic lupus erythematosus. Additionally, the company is developing CLYM116, a preclinical-stage anti-APRIL monoclonal antibody for immunoglobulin A nephropathy and other B-cell mediated diseases. Climb Bio aims to address unmet medical needs in autoimmune and inflammatory conditions.

Climb Bio Inc is listed on the Nasdaq Capital Market (NasdaqGM) under the ticker symbol CLYM. The company trades in US Dollars (USD), as it is headquartered in the United States. Being listed on a major US exchange provides liquidity and access to a broad investor base. The NasdaqGM is part of the Nasdaq stock exchange, which is known for hosting many biotechnology and technology companies. Investors can trade CLYM shares during regular market hours, and the stock is subject to US securities regulations.

Climb Bio Inc operates in the Healthcare sector, specifically within the Biotechnology industry. As a biotechnology company, it focuses on researching and developing novel therapies for diseases, particularly immune-mediated conditions. The biotechnology industry is characterized by high research and development costs, long development timelines, and significant regulatory oversight. Climb Bio's work involves monoclonal antibodies and other biologic drugs, which are complex molecules derived from living organisms. This sector is distinct from pharmaceuticals in that biotech companies often target specific molecular pathways with innovative treatments.

Climb Bio Inc is headquartered in Wellesley Hills, Massachusetts, United States. The company was incorporated in 2018 and was formerly known as Eliem Therapeutics, Inc. before rebranding to Climb Bio in October 2024. The name change reflects a shift in strategic focus toward immune-mediated diseases. Being based in Massachusetts places the company in a major biotech hub with access to talent, research institutions, and potential partnerships. The company serves primarily the US market, though its therapies could eventually address global unmet medical needs.

Climb Bio Inc's main product candidate is budoprutug, an anti-CD19 monoclonal antibody targeting B-cell mediated diseases. Budoprutug is in Phase 2 clinical trials for primary membranous nephropathy (a kidney disease) and immune thrombocytopenia (a bleeding disorder), and in Phase 1b trials for systemic lupus erythematosus (an autoimmune disease). Additionally, the company is developing CLYM116, a preclinical-stage anti-APRIL monoclonal antibody for immunoglobulin A nephropathy and other B-cell mediated conditions. These candidates aim to modulate the immune system by targeting specific proteins on B cells or related pathways, potentially offering new treatment options for patients with limited alternatives.